By applying anti‐VEGF treatment at various time points during inhibition of EGFR, they concluded that angiogenesis is the dominant mechanism leading to resistance to EGFR inhibitor and that combination with anti‐VEGF treatment is able to inhibit tumor relapse, which was validated by in vivo experimental data from mice with brain tumors (Tonra et al., 2006). This evidence concerns the gene EGFR and neoplasm.